Greenwich LifeSciences, Inc.

    Jurisdiction
    United States
    ISIN
    US3968791083 (GLSI)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €3.08K
    Gross margin
    25.0%
    EBIT
    -€14.29M
    EBIT margin
    -463,924.4%
    Net income
    -€14.14M
    Net margin
    -458,858.7%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 13K $119.25K -10K Sell

    Add to watchlist

    Notifications